- Home
- ATRC vs CGON Comparison
ATRC vs CGON Comparison
Compare ATRC & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRC
- CGON
- Stock Information
- Founded
- ATRC 2000
- CGON 2010
- Country
- ATRC United States
- CGON United States
- Employees
- ATRC N/A
- CGON N/A
- Industry
- ATRC Medical/Dental Instruments
- CGON
- Sector
- ATRC Health Care
- CGON
- Exchange
- ATRC Nasdaq
- CGON NYSE
- Market Cap
- ATRC 1.5B
- CGON 1.3B
- IPO Year
- ATRC 2005
- CGON 2024
- Fundamental
- Price
- ATRC $30.89
- CGON $24.91
- Analyst Decision
- ATRC Strong Buy
- CGON Strong Buy
- Analyst Count
- ATRC 10
- CGON 11
- Target Price
- ATRC $49.60
- CGON $62.90
- AVG Volume (30 Days)
- ATRC 716.7K
- CGON 2.0M
- Earning Date
- ATRC 04-29-2025
- CGON 05-16-2025
- Dividend Yield
- ATRC N/A
- CGON N/A
- EPS Growth
- ATRC N/A
- CGON N/A
- EPS
- ATRC N/A
- CGON N/A
- Revenue
- ATRC $480,076,000.00
- CGON $1,139,000.00
- Revenue This Year
- ATRC $14.60
- CGON N/A
- Revenue Next Year
- ATRC $12.58
- CGON $16,237.24
- P/E Ratio
- ATRC N/A
- CGON N/A
- Revenue Growth
- ATRC 15.79
- CGON 461.08
- 52 Week Low
- ATRC $18.94
- CGON $14.80
- 52 Week High
- ATRC $43.11
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- ATRC 45.77
- CGON 52.35
- Support Level
- ATRC $28.52
- CGON $21.00
- Resistance Level
- ATRC $31.82
- CGON $25.12
- Average True Range (ATR)
- ATRC 1.53
- CGON 2.29
- MACD
- ATRC -0.02
- CGON 0.12
- Stochastic Oscillator
- ATRC 36.25
- CGON 38.20
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.